Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Towa Begins Priority Supply of 23 APIs, Mostly under Shipment Curbs, to Quake-Hit Area
January 26, 2024
- Shionogi Partners with Niremia Collective to Fund Well-Being Tech Startups
January 26, 2024
- BlueRock In-Licenses Fujifilm’s iPSC Therapy for Ocular Disease
January 25, 2024
- Kyowa Kirin Closes Acquisition of UK Gene Therapy Player Orchard
January 25, 2024
- Takeda’s Cuvitru Now Available in Japan as Its First SC Immunoglobulin
January 25, 2024
- Ono Revs Up to Boost Global Presence, Launches New HR Scheme
January 24, 2024
- Astellas to Discontinue IBS Med Colonel in Product Consolidation
January 24, 2024
- Astellas to Transfer Distribution Rights for Antibacterial Geninax to Taisho
January 24, 2024
- Mitsubishi Tanabe, Pfizer to Copromote 5-in-1 Vaccine Gobik
January 24, 2024
- Prefilled Syringe Versions of Hizentra Approved in Japan: CSL
January 23, 2024
- Nippon Shinyaku Snags EU Orphan Tag for EGPA Drug
January 23, 2024
- Moderna Japan Files 0.5 mL Vial Formulation for Spikevax
January 22, 2024
- Employee Sues Alexion for Sidelining in Reprisal against Whistleblowing
January 19, 2024
- Daiichi, Mitsubishi Curb MR Vaccine Shipments in Response to Takeda’s Recall
January 19, 2024
- LEO Pharma Poised to Build Presence in Japan as Dermatology Leader: CEO
January 19, 2024
- Sawai Exits US Biz to Cope with GMP and Supply Issues in Japan
January 18, 2024
- Takeda’s Hyqvia Earns US Nod for CIDP Maintenance Therapy
January 18, 2024
- US Patent Office Nixes Seagen Patent in ADC Row: Daiichi Sankyo
January 18, 2024
- Ono Deplores Regulator’s Decision on Opdivo Spillover Re-Pricing
January 18, 2024
- Parmodia Tops November GP Rep Promotion List, Dayvigo HP Champion for 4th Month
January 18, 2024
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…